All In Biotech

Drug Trial Radar · NCT07022483

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

710

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Feb 26, 2030

Study completion Mar 23, 2032

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Conditions

  • Endometrial Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    T-DXd will be administered at a dose of 5.4 mg/kg IV Q3W.

  • ChemotherapyDrug

    Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without radiation therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local AssessmentTime frame: From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months

Locations

86 sites in 15 countries. Site status is shown where the registry gives one.

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • Parkview Research Center

    Fort Wayne, Indiana · Recruiting

  • Trials365 LLC

    Shreveport, Louisiana · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Coon Rapids, Minnesota · Recruiting

  • FirstHealth of the Carolinas, Inc.

    Pinehurst, North Carolina · Recruiting

  • University of Cincinnati Physicians Group, LLC

    Cincinnati, Ohio · Recruiting

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Medical Group Gynecologic Oncology Sioux Falls

    Sioux Falls, South Dakota · Recruiting

  • Texas Oncology, P.A. - Tyler

    Sioux Falls, South Dakota · Recruiting

  • Texas Oncology - Bedford

    Bedford, Texas · Recruiting

  • Texas Oncology San Antonio Medical Center

    San Antonio, Texas · Recruiting

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Sanatorio Allende Cerro

    Córdoba, Argentina · Recruiting

  • Centro de Investigaciones Medicas Mar del Plata

    Mar del Plata, Argentina · Recruiting

  • Instituto de Oncologia de Rosario

    Rosario, Argentina · Recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina · Recruiting

  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica

    San Juan, Argentina · Recruiting

  • Biocenter

    Concepción, Chile · Recruiting

  • Centro de Estudios Clinicos SAGA

    Santiago, Chile · Recruiting

  • Centro de Investigaciones Clinicas de la Universidad Catolica

    Santiago, Chile · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, China · Recruiting

  • Shanghai First Maternity and Infant HospitalShanghai First Maternity and Infant Hospital

    Shanghai, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Yantai Yuhuangding Hospital

    Yantai, China · Recruiting

  • Centre Francois Baclesse

    Caen, France · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.